Biogen (BIIB) Enterprise Value (2009 - 2026)
Biogen (BIIB) recorded quarterly Enterprise Value of -$4.3 billion in Q1 2026, down 12.24% quarter-over-quarter from -$3.8 billion in Q4 2025, and down 64.83% on a YoY basis from -$12.2 billion in Q1 2025.
Biogen (BIIB) Enterprise Value (2009 - 2026) Analysis & Trends
Biogen's Enterprise Value history runs 18 years deep, the most recent figure standing at -$4.3 billion for Q1 2026.
- In Q1 2026, Enterprise Value fell 64.83% year-over-year to -$4.3 billion; the TTM figure through Mar 2026 stood at -$4.3 billion (down 64.83% YoY), while the FY2025 annual figure was -$3.8 billion, down 60.66% from the prior year.
- Enterprise Value was -$4.3 billion for Q1 2026 at Biogen, down from -$3.8 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.0 billion in Q4 2023 to a low of -$6.1 billion in Q2 2023.
- Historically, Enterprise Value has averaged -$3.4 billion across 5 years, with a median of -$3.8 billion in 2022.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 78.73% in 2024, then tumbled 141.84% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$4.9 billion in 2022, then soared by 78.58% to -$1.0 billion in 2023, then plunged by 126.21% to -$2.4 billion in 2024, then sank by 60.66% to -$3.8 billion in 2025, then fell by 12.24% to -$4.3 billion in 2026.
- The last three Enterprise Value figures came in at -$4.3 billion (Q1 2026), -$3.8 billion (Q4 2025), and -$4.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | -4.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.28 Bn |
| Dec 31, 2025 | -3.82 Bn |
| Sep 30, 2025 | -3.96 Bn |
| Jun 30, 2025 | -2.76 Bn |
| Mar 31, 2025 | -2.60 Bn |
| Dec 31, 2024 | -2.38 Bn |
| Sep 30, 2024 | -1.70 Bn |
| Jun 30, 2024 | -1.91 Bn |
| Mar 31, 2024 | -1.07 Bn |
| Dec 31, 2023 | -1.05 Bn |
| Sep 30, 2023 | -2.29 Bn |
| Jun 30, 2023 | -6.08 Bn |
| Mar 31, 2023 | -5.05 Bn |
| Dec 31, 2022 | -4.90 Bn |
| Sep 30, 2022 | -4.92 Bn |
| Jun 30, 2022 | -4.81 Bn |
| Mar 31, 2022 | -3.77 Bn |
| Dec 31, 2021 | -3.74 Bn |
| Sep 30, 2021 | -2.50 Bn |
| Jun 30, 2021 | -2.59 Bn |